This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.

This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.
PHILADELPHIA—At the first Plenary Session of ACR Convergence 2022, on Saturday, Nov. 12, speakers shared key research findings on the efficacy and safety of methotrexate as a co-therapy with pegloticase in refractory gout, the effectiveness of rituximab and cyclophosphamide in connective tissue disease associated-interstitial lung disease and the value of remote education for primary care…
Oshrat E. Tayer-Shifman, MD; Kimberley Yuen, BSc, MD; Zahi Touma, MD, PhD, FACP, FACR; William Daniel Soulsby, MD; Aleksandra Kostic, BSE; Valia Leifer, MA; & Elena Losina, PhD, MSC |
MoCA as a Screening Test in SLE Assessing the utility of the Montreal Cognitive Assessment (MoCA) By Oshrat E. Tayer-Shifman, MD, Kimberley Yuen, BSc, MD, & Zahi Touma, MD, PhD, FACP, FACR Why was this study done? Cognitive impairment is a common manifestation of systemic lupus erythematosus (SLE), with a prevalence of 40% based on…
Patrice Fusillo |
During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…
Vania Lin, MD, MPH, Rebecca Johnson, MD, & Lisa Suter, MD |
Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…
Katie Robinson |
The mission of the Rheumatology Research Foundation, a division of the ACR, is to advance research and training to improve the health of patients living with rheumatic disease. It supports career advancement, mentorship, professional development and education of professionals working in the disciplines essential to these patients.1 “The Foundation understands that the support of Association…
Anne R. Bass, MD, a professor of medicine at Weill Cornell Medical College/Hospital for Special Surgery, New York, has had a unique career path combining clinical practice with academia. Dr. Bass knew “pretty early” in her academic career that she would be going into medicine. She loved science, but also knew that she wanted to…
It is better to be feared than loved. The associate dean of student affairs at my medical school embraced this motto. Although the dean of the medical school was titularly in charge, it was the associate dean who kept the school running. And we all feared her, just a little bit. Without ever raising her…
Like solving sudoku, planning the ACR annual meeting requires an ability to recognize patterns and employ focused logical thinking, all the while remaining undaunted by the various paths possible to complete a grid from what looks like, at initial glance, an incomprehensible labyrinth of options. The patterns in this situation are not numbers, but sessions,…
Fazila Aseem, MD, MPH, Alexander D. Jeffs, MD, Enid Y. Sun, MD, MPH, Randaline R. Barnett, MD, Courtney Blodgett, AG-ACNP, Winnie Lau, MD, Casey Olm-Shipman, MD, MS, Matthew F. Sharrock, MD, Rhonda Cadena, MD, Yueh. Z. Lee, MD, PhD, Alfredo C. Rivadeneira, MD, & Clio A. Rubinos, MD, MS |
Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…